CYRX

Based on Cryoport, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Cryoport do?

Cryoport provides temperature-controlled logistics solutions for life sciences companies. Its services cover shipment management, real-time tracking, cryogenic storage, and biological specimen archiving. The company primarily serves biopharma, animal health, and human reproductive medicine customers across multiple global regions.

Does CYRX pay dividends?

No, Cryoport does not currently pay a dividend. The company reinvests available capital into its logistics platform and operational growth rather than returning cash to shareholders. Investors seeking regular income should note this before considering the stock.

When does CYRX report earnings?

Cryoport follows a standard quarterly earnings cadence for US-listed companies. Specific dates are not covered by our data source. For upcoming reporting dates and recent results, check Cryoport's official investor relations page.

Is CYRX a good stock to buy?

UQS Score rates CYRX as Below Average, reflecting Weak Quality and Moat pillars alongside a Neutral Growth and Risk profile. The Valuation pillar is Attractive, which may interest contrarian investors. The full pillar breakdown is available to UQS Pro members.

Is CYRX overvalued?

Based on the UQS Valuation pillar, CYRX is currently rated Attractive, suggesting the stock may be trading below what the underlying business profile would typically command. This does not constitute a price prediction — see the full analysis for context.

How does CYRX compare to its competitors?

Cryoport occupies a specialized niche in life sciences cold-chain logistics, which differs meaningfully from broader freight peers like Radiant Logistics or Forward Air. Its platform-driven model targets biopharma and cell therapy shipments rather than general commercial cargo.

What is CYRX's market cap bracket?

Cryoport is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but typically carries greater volatility and liquidity risk compared to large- or mega-cap peers.

Who founded Cryoport?

Cryoport was founded in 2005. Details on the founding team are widely available through the company's public filings and corporate history disclosures on its investor relations website.

Is CYRX a long-term quality indicator?

As a long-term quality indicator, CYRX currently scores Below Average on the UQS composite. The Weak Moat and Quality pillars suggest the business has not yet established the durable competitive advantages typically associated with strong long-term compounders. Monitoring improvement in these pillars over time would be key.

What is the main competitive advantage of Cryoport?

Cryoport's primary differentiator is its purpose-built platform — Cryoportal — designed specifically for the regulatory and handling complexity of biological shipments. However, the UQS Moat pillar rates this advantage as Weak, indicating the company has not yet translated its specialization into a clearly defensible market position.

What sector does CYRX belong to?

Cryoport is classified under the Industrials sector, specifically within specialized logistics services. Its customer base, however, is heavily concentrated in life sciences, giving it characteristics that overlap with healthcare services companies.

Is CYRX a growth stock or value stock?

Based on UQS pillar labels, CYRX shows a Neutral Growth profile and an Attractive Valuation, placing it in an ambiguous position — neither a high-conviction growth name nor a classic deep-value play. It may appeal to investors looking for a discounted entry into a niche logistics theme.

Cryoport, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.

Cryoport, Inc. demonstrates healthy growth trends across revenue and earnings.

Cryoport, Inc. has some risk factors including moderate leverage or solvency concerns.

Cryoport, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.

Cryoport, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CYRX.

The UQS (Unified Quality Score) for Cryoport, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Cryoport, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Cryoport, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.